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Abstract
This study on patients with localized prostate cancer was set up to investigate
valuable differences using ﬂattened beam (FB) and ﬂattening ﬁlter free (FFF) mode
in the application of intensity-modulated radiotherapy (IMRT) and volumetric-
modulated arc therapy (VMAT). For ten patients, four different plans were calcu-
lated with Oncentra planning system of Elekta, using Synergy machines: IMRT and
VMAT, with and without ﬂattening ﬁlter. Homogeneity and conformity indexes, dose
to the organs at risk, and measurements of peripheral dose and dosimetric plan veriﬁ-
cation including record of the delivery times were analyzed and statistically evaluated.
The indexes for homogeneity and conformity (CTV and PTV) are either advantageous
or not signiﬁcantly different for FFF compared to FB with one minor exception.
Regarding the doses to the organs at risk and the measured peripheral dose, equiva-
lent or lower doses were delivered for FFF than with FB. Furthermore, the delivery
times were signiﬁcantly shorter for FFF. VMAT compared to IMRT reveals beneﬁts or
at least equivalent values. VMAT-FFF combines the most advantageous plan quality
parameters with the shortest delivery times and reduced peripheral dose and is there-
fore recommended for the given equipment and cancer localization.
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1 | INTRODUCTION
Fluence modulating treatment techniques like intensity-modulated
radiotherapy (IMRT) and volumetric-modulated arc therapy (VMAT)
are well established for many tumor sites. These techniques now
enable the clinical application of linear accelerators (linacs) with ﬂat-
tening ﬁlter free mode (FFF), thus obtaining a much higher dose rate
than in the standard ﬂattened beam mode (FB). The ﬁrst reported
clinical investigations of FFF referred to radiosurgery1 and aimed for
shorter treatment times. A reduction of the treatment time reduces
the probability of intrafraction motion of the target and organs at
risk, which has been demonstrated to be not negligible for the treat-
ment of prostate cancer.2–8 Another property of FFF is the diminu-
tion of head scatter, as the ﬂattening ﬁlter is one of its main
sources.9,10 This should affect the peripheral dose (PD), which is a
factor of secondary cancer probability. Effects of FFF on treatment
plans with IMRT and VMAT technique are compared to FB plans in
this planning study, evaluating treatment times, plan quality, and PD.
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Although there are some other publications regarding the treat-
ment of patients with prostate carcinoma using linacs with FFF
mode, they refer to other types of rotational technique and manu-
facturers and different treatment planning systems (TPS).11–13 How-
ever, the design of the linac head affects the PD14 and the
penumbra of the beam. The desktop software, the hardware of the
linac, and the TPS inﬂuence the treatment time. Kry et al.15 showed
that there is also a dependency of the PD on the ﬁeld size and the
amount of modulation. Therefore investigations with the same or
similar equipment,16,17 but different targets cannot simply be trans-
ferred. This work demonstrates for the ﬁrst time a comparison of FB
and FFF plans for prostate cancer therapy with the given equipment
of linacs and TPS.
2 | MATERIAL AND METHODS
2.A | Patients, regions of interest (ROI), and dose
prescription
Ten consecutive patients with histologically proven, previously
untreated localized prostate cancer were included in this planning
study. All patients had given their informed consent to take part in the
study. DICOM data sets including delineated regions of interest were
taken from a former investigation.18 The mean age of the patients was
71 yr. For the planning CT study, they were immobilized in supine
position in a vacuum mattress (Blue-BAGTM BodyFIX, Medical Intelli-
gence, Schwabm€unchen, Germany) according to Boehmer et al.19 In
each slice with an effective distance of 2.5 mm, the following volumes
of interest were delineated following the description of Bos et al.20:
As target volumes the gross target volume (GTV: prostate gland and
seminal vesicles), the clinical target volume (CTV: 5-mm three-dimen-
sional margin added to the GTV excluding the rectal volume), the plan-
ning target volume (PTV: 10-mm three – dimensional margin added to
the GTV without respect to the rectum), and as organs at risk (OAR)
the rectal volume (according to Guckenberger et al.21), urinary bladder
and femoral heads. To achieve high plan quality, two additional vol-
umes were constructed. First, the PTV with an added margin of 5 mm
was subtracted from the rectum volume, resulting in the posterior part
of the rectum; second, the CTV was subtracted from the PTV
(PTV  CTV) to model the dose gradient in this region.
Criteria were formulated to build a complete set of accepted val-
ues which represents the dose prescription in the sense of ICRU
report 83:22 The average dose to the CTV should be in the range of
71.5 Gy to 73.7 Gy, allowing a deviation of 1.5% in the total dose.
For the PTV, 56.4 Gy were set as acceptance value for D98%
PTV. For
the OAR, we required the volume of the rectum receiving up to
70 Gy to be smaller than 20%, the volume of the urinary bladder and
the femoral heads receiving up to 50 Gy to be smaller than 50%.
2.B | Linear accelerator
The linac used in the TPS and for the measurements is an Elekta
SynergyTM with AgilityTM head (Elekta AB, Stockholm, Sweden), which
is equipped with 80 interdigitating leaf pairs, having 5 mm leaf width
projected to the isocenter. 6 MV photons were applied in FB and
FFF mode. It has been shown earlier that the beam quality is very
similar for both modes,23 as it is common for Elekta linacs.24 The
maximum dose rate is 500 monitor units (MU) per minute in FB
mode and 1700 MU per minute in FFF. The desktop software is
Integrity 3.1 and the record and verify system Mosaiq 2.50.
2.C | Treatment planning system
The treatment planning was performed with Oncentra External
Beam v4.5 (Nucletron, an Elekta AB). The system has been com-
missioned especially for VMAT application with BeamModulatorTM
head ﬁrst25 and later also for AgilityTM head.23 The software sup-
ports variable gantry speed, which was set to a maximum value
of 6.0 degree per second, and variable dose rate with a set mini-
mum value of 20 MU per minute. Static and dynamic minimum
leaf gaps were set to 1.00 cm. Calculations were performed using
the collapsed cone algorithm. The optimizer module in Oncentra
for IMRT and VMAT has been developed by RaySearch Laborato-
ries (Stockholm, Sweden), as the similar SmartArc module inte-
grated in the Pinnacle³ TPS (Philips, Amsterdam, Netherlands), and
also the RayArc module in the proprietary RayStation TPS. For
IMRT optimization, the direct step-and-shoot algorithm was
used.26
2.D | Planning
The dose optimization parameters and fractionation schedule were
taken from the above mentioned study:18 The plans were set up
with simultaneous integrated boost in 33 fractions aiming for
59.4 Gy minimum dose to the PTV (being 105% of the acceptance
value for D98%
PTV of 56.4 Gy as described above) and 71.0 Gy mini-
mum dose and 74.2 Gy maximum dose to the CTV, which was used
as the boost treatment volume. The average value of minimum and
maximum dose is 72.6 Gy. This corresponds to a single fraction dose
of 2.2 Gy. The CTV objectives were set stronger than clinically
achievable to force the DVH to a steep downfall and to get similar
average dose values for each single plan. Setting a speciﬁc dose
value to a dose point or average dose of a volume is not possible in
the optimizer module of the Oncentra TPS. The same set of dose
volume objectives (DVO) has been used for both modes, FB and
FFF, IMRT as well as VMAT to make the results comparable18,27,28
(Table 1). For the same reason, individual plan optimizations with
variations of weights or objectives have not been performed. The
surrounding dose fall-off objective is used to model the dose gradi-
ent from the surface of the PTV into the normal tissue.29 For all
plans, the resulting average dose in the CTV was set to 100%. No
rescaling of this dose to a speciﬁc dose value has been performed,
as this may result in additional dose to the normal tissue and OARs
which are part of the optimization process as well.30 As also stated
for another TPS,31 the dose to the target is a free parameter of the
cost function. Therefore, the resulting average dose in the CTV was
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taken as speciﬁcation dose, thus representing the direct result of the
objective function.
The center of the CTV was positioned to the isocenter. The cal-
culation grid had a resolution of 0.25 cm.
The IMRT planning followed26 using seven equispaced beams
with gantry angles of 0°, 51°, 103°, 154°, 206°, 257°, and 309°. The
collimator was set to 0°. Additional parameters were adjusted: At
least six open leaf pairs, a maximum number of 60 segments for the
complete plan, a minimum number of 4 MU per segment, and the
minimum ﬁeld size was set to 9.0 cm².
The VMAT optimization used parameters which were deduced
from our above mentioned earlier investigation:18 gantry single arc
rotation from 182° to 178° with gantry spacing of 4° between two
control points, collimator angle 45°, and a maximum delivery time of
110 s.
The planning was performed for the complete study by the same
specialist medical physicist. After the ﬁrst optimization and ﬁnal dose
calculation, a second cycle of optimization and dose calculation
followed for each plan.
2.E | Plan evaluation and statistics
For the evaluation of the plan quality, the following parameters were
regarded. The homogeneity index HI in the CTV was deﬁned accord-






CTV are the dose to 2% and 98% of the CTV, respectively.
Dav
CTV is the average dose to the CTV, which was set to 100%.
The conformity indexes in the CTV (CICTV) and in the PTV (CIPTV)
were calculated according to Paddick.32 CICTV: = TV71 Gy
2/
(V71 Gy 9 V
CTV) and CIPTV: = TV59.4 Gy
2/(V59.4 Gy 9 V
PTV) use the
minimum values of Table 1 prescribed to the CTV (71 Gy) and PTV
(59.4 Gy), respectively. TV71 Gy and TV59.4 Gy describe the volumes
within the corresponding target receiving these dose values, and
V71 Gy and V59.4 Gy are the equivalent volumes within the patient
contour. VCTV and VPTV are the target volumes. D98%
PTV–CTV — the
dose to 98% of the PTV  CTV — was regarded as parameter for
the minimum dose to the PTV.
The following dose and dose volume values were evaluated: The
dose exceeded by 50% of the volume to the urinary bladder
D50%
UB, to both femoral heads (D50%
lFH and D50%
rFH) and to the
rectum volume D50%
R and the dose value to the posterior part of
the rectum D2%
Rpost which is exceeded by 2% of the volume. Addi-
tional parameters were taken from the QUANTEC review sum-
mary:33 The percentage of volume receiving less than a speciﬁed




R) and 70 Gy and 65 Gy for the urinary bladder
(V70 Gy
UB, V65 Gy
UB). Furthermore, the total number of MU was
recorded.
The statistical analysis was performed using the Wilcoxon test in
IBM SPSS Statistics 23 (IBM Corporation, Armonk, NY, USA). The
test was run with a signiﬁcance level of 0.05. First, the FFF plans
were compared to the FB plans for both IMRT and VMAT sepa-
rately. Second, the IMRT and VMAT plans were compared, broken
down into FFF and FB.
2.F | Measurements
All plans were dosimetrically veriﬁed with a 2D-array MatriXX Evolu-
tion (IBA, Schwarzenbruck, Germany) in stacks of solid water, type
RW3 (PTW, Freiburg, Germany) using a hybrid technique as
described previously18,34,35. The array was positioned in the horizon-
tal isocenter plane and connected to a gantry angle sensor attached
to the gantry. Every 200 ms, the gantry angle and a dose matrix
were acquired by the software OmniPro I’mRT v. 1.7a of the same
manufacturer automatically. A correction factor matrix was used to
correct the matrices for angular dependencies, including couch atten-
uation. The sum of the corrected matrices was compared to the cal-
culated dose by gamma evaluation36 with a dose tolerance of 3% of
the maximum dose and a distance to agreement of 3 mm. The dose
calculations in the TPS were performed with a dose grid of 1.5 mm
in the measurement plane. We restricted the area of the evaluation
to dose values above 10% of the maximum dose as recommended
by Ezzell et al.37 The percentage of pixels in range (c ≤ 1) of the
gamma evaluation was registered.
TAB L E 1 Dose volume objectives used in the TPS Oncentra.
ROI Type Dose level (Gy) Volume (%) Weight
CTV Minimum dose 71.0 100 3000
CTV Maximum dose 74.2 0 3000
PTV–CTV Minimum dose 59.4 100 3000
PTV–CTV Maximum dose 71.0 0 3000
Urinary bladder Maximum dose volume 50 50 1000
Rectum Maximum dose volume 70 20 1000
Rectum Maximum dose volume 50 60 1000
Rectum Maximum dose 74.2 0 1000
Posterior rectum Maximum dose 50 0 1000
Left and right femoral head Maximum dose volume 50 50 300
Outline Surrounding dose fall-off 59.4 to 29.7 within 5 mm – 500
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For the evaluation of the PD, we followed the description of
Dobler et al.16 One additional point dose value (PDstack) was
recorded in a similar stack of RW3 phantom slabs as the 2D-array
on the axis of gantry rotation in a distance of 31 cm toward the
linac structure. To investigate more points, we added the upper part
of a male Alderson phantom (RSD Inc., Long Beach, CA, USA)
(Fig. 1). Two slices of the phantom were substituted by similar
shaped parts of PA material with bores for ionization chambers in a
distance of 50.5 cm and 65.5 cm, respectively. The dose to these
points is representative for the lower esophagus (PDesoph) and the
thyroid gland (PDthyr). Georg et al.10 stated that the PD cannot easily
be calculated with the TPS and Covington et al.38 explicitly recom-
mend measurements. Therefore, no calculations in these points were
performed. The applied ionization chambers were of type 30016 and
23332 (0.3 cm³ both), connected to Unidos dosimeters (PTW, Frei-
burg, Germany).
To assess the delivery times (DT), they were measured from
pressing the start button to the last beam off.
3 | RESULTS
All plans met the acceptance criteria as formulated for dose pre-
scription. Due to the fact that the focus is on the comparison of
FB and FFF mode, the statistical results are grouped in Table 2 cor-
respondingly. Differences between IMRT and VMAT are given in
the text only to gain clarity. A DVH for a speciﬁc patient is shown
in Fig. 2.
3.A | Plan quality
The indexes for homogeneity and conformity (HI, CICTV, and CIPTV)
are either advantageous or not signiﬁcantly different for FFF com-
pared to FB with one exception: FB VMAT plans have a slightly better
CIPTV. VMAT plans are signiﬁcantly superior compared to IMRT plans.
The average dose to the CTV is very similar for all groups. There
is no signiﬁcance comparing VMAT and IMRT in FB mode
(P = 0.185), but it is signiﬁcantly higher for VMAT in FFF mode
(P = 0.007).
For D98%
PTV–CTV, all values are similar. Nevertheless, VMAT-FFF
was signiﬁcantly higher than FB. There was no signiﬁcant difference
for VMAT compared to IMRT.
OAR dose values are lower for IMRT-FFF than FB. VMAT plans
are equivalent for both modes except the measured PD, which is sig-
niﬁcantly lower with FFF in the three measured points. VMAT values
are either signiﬁcantly lower or not signiﬁcantly different compared
to IMRT in the regarded OAR and PD points.
The dose values to the femoral heads (D50%
lFH and D50%
rFH) are
rather close and stayed at about half of the prescribed values for
the objective function. Therefore, they were not further regarded
according to Kjaer-Kristoffersen et al.39 The volume data evaluated
according the QUANTEC review33 show as a general result that in
no single plan the given maximum percentage volume values were
reached which means V70 Gy
R < 20%, V60 Gy
R < 35%, V50 Gy
R < 50%,
V70 Gy
UB < 35%, and V65 Gy
UB < 35%. The average values stay far
below as can be seen from Table 2. Although some differences
between FB and FFF are statistically signiﬁcant, they are smaller
than 2% of the organ volume for the average values.
3.B | Plan veriﬁcation and efﬁciency
All 40 plans passed the gamma evaluation. The average passing rates
in the four groups were between 98.2% and 99.5% without signiﬁ-
cant difference between FB and FFF or IMRT and VMAT.
FFF plans are delivered signiﬁcantly faster than FB plans. VMAT
takes less than a third of the delivery time of IMRT plans. FFF plans
require more MU than FB plans and VMAT requires more than IMRT
(FB and FFF P = 0.007 both).
4 | DISCUSSION
The comparison of FB and FFF mode shows a clear advantage for
FFF as can be seen in Table 2. Only in a few rows, there are
F I G . 1 . Measurement setup with 2D-
array, ionization chambers and Alderson
phantom.
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superior values for FB. However, less MU for FB are only a technical
parameter, which does not have any impact for the plan quality or
patient comfort. The second advantageous parameter is the CIPTV at
VMAT plans. Nevertheless, the difference is very small. On the other
hand, the CICTV is distinctly better for FFF mode. Third, some OAR
volumes receiving a speciﬁed dose are smaller for FB than for FFF.
Partly this can be traced to a smaller part of the PTV receiving the
minimum dose required by the objectives and results therefore in a
smaller CIPTV. However, these differences are small too, in most
cases less than 1% of the volume of the OAR, especially in compar-
ison to the large standard deviation. Therefore, the toxicity will be
similar.
We explained in section 2.D that the minimum and maximum
dose values for the CTV were set stronger than could be achieved.
Therefore, the HI as documented in Table 2 does not match these
limits. However, ICRU report 8322 states that even the limits of the
ICRU report 6240 might be too conﬁning for IMRT plans. Applying
these limits, an even larger HI might be acceptable. There is a small
TAB L E 2 Overview of dose volume statistics, delivery times and MU, showing average values and standard deviation.
Mode
IMRT-FB IMRT-FFF VMAT-FB VMAT-FFF
CTV HI in % 8.6  2.9 8.3  1.4 7.3  2.0 7.5  2.0
CICTV 0.77  0.06 0.81  0.03 0.83  0.04 0.86  0.03
Dav
CTV in Gy 72.2  0.2 72.4  0.3 72.4  0.3 72.8  0.1
PTV CIPTV 0.64  0.07 0.76  0.09 0.85  0.06 0.84  0.06
D98%
PTV–CTVin Gy 58.9  1.4 59.1  1.1 58.2  1.3 58.7  1.4
OAR D50%
UB in Gy 41.1  12.1 37.1  11.4 32.4  11.0 32.4  11.2
D50%
lFH in Gy 25.7  5.0 23.4  4.4 24.2  5.4 23.7  4.8
D50%
rFH in Gy 25.8  4.7 23.7  4.9 25.7  4.6 25.4  4.6
D50%
R in Gy 44.1  1.7 41.6  2.6 38.7  3.5 39.1  3.7
D2%
Rpost in Gy 50.0  1.1 48.9  0.8 48.0  1.1 48.4  0.8
PDstack in mGy 3.6  0.4 3.0  0.3 3.4  0.4 2.5  0.4
PDesoph in mGy 1.5  0.1 1.3  0.1 1.1  0.1 0.7  0.1
PDthyr in mGy 1.3  0.1 1.1  0.2 1.2  0.1 0.6  0.1
V70Gy
R in % 1.8  2.7 2.7  3.2 3.0  2.3 2.7  3.2
V60Gy
R in % 14.1  6.8 15.6  6.8 15.9  6.0 16.0  6.2
V50Gy
R in % 29.7  6.7 28.5  7.5 27.2  7.0 27.7  6.7
V70Gy
UB in % 7.3  4.4 7.1  4.4 7.3  4.3 8.1  4.5
V65Gy
UB in % 15.1  6.5 13.4  6.2 12.6  5.9 13.3  5.9
Efﬁciency MU 439  23 513  42 515  57 566  33
DT in s 294  21 276  29 84  2 77  3
The average values and sample standard deviation are over all ten plans per group. Values which are superior with statistical signiﬁcance for the
































F I G . 2 . DVH for the different plans for
one speciﬁc patient.
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advantage for FFF in IMRT (statistically signiﬁcant) and a similar dif-
ference without signiﬁcance for FB in VMAT. The statistically signiﬁ-
cant superiority of VMAT over IMRT is the more considerable
ﬁnding regarding the HI. The prescribed minimum dose to the PTV
of 59.4 Gy has not been reached by the average values of D98%
PTV–
CTV. As the PTV is adjacent to the rectum, the objectives for this
OAR worked limiting. The maximum dose to the posterior rectum
had been set to 50.0 Gy and the average values of D2%
Rpost came
close up. Therefore, it must be expected that a change in the
weights of these objectives might improve the minimum dose to the
PTV, but increase the dose to the posterior rectum. Crijns et al.41
observed in their planning study for prostate treatment, that none of
the RapidArc plans (with ﬂattened beams) was within the rectum
constraint.
Although the dose to the femoral heads might be improved by
setting lower objectives, this could be realized only by increasing the
dose from the other directions. A raised dose to the rectum or blad-
der would be the consequence. To avoid this, the objectives for the
femoral heads were not reduced.
The plan quality of IMRT plans might increase with additional
ﬁelds. Bell et al. report a standard of 11 beams.13 However, they did
not ﬁnd clinically relevant differences compared to their mArc rota-
tion technique (which is described different from VMAT), which also
resulted in shorter delivery times and therefore was recommended.
Kragl et al.9 and Georg et al.10 pointed out, that the PD is a com-
plex function which depends on multiple factors as e.g., the distance
from the primary beam. Removing the ﬂattening ﬁlter eliminates the
main source of photon scatter in the treatment head and thus
explains lower measured values for FFF as it has also been reported
by Dobler et al.16 with a similar experimental setup, Bell et al.13 and
Dzierma et al.11 who measured at three positions at an Alderson
phantom, and Kragl et al.9 performing IMRT measurements with dif-
ferent dosimetry systems. Similar to Dzierma et al., we found that the
average values of the PD decreased with increasing distance. How-
ever, this was not valid in each single case, comparing PDesoph and
PDthyr. These dose values are especially inﬂuenced by the treatment
head leakage10 and depend on the current collimator conﬁguration.
Closer to the isocenter, the patient scatter becomes more and more
dominating.
VMAT compared to IMRT results in a further reduction of the
PD which seems contradictory to the increased number of MU. This
is again in accordance with the results of Dobler et al.16 at another
localization and Bell et al.13 with another rotation technique (mArc).
Reduced PD will result in a reduced secondary cancer risk.
As mentioned in the ﬁrst paragraph of this section, the number of
MU is higher for FFF compared to FB. Although it seems rather obvi-
ous that additional MU are necessary to gain a uniform dose distribu-
tion with an inhomogeneous proﬁle, there exist contrary ﬁndings for
IMRT treatment of prostate cancer with different equipment42 which
might result from a constructional ﬂaw in the IMRT segmentation pro-
cess of the other TPS. Furthermore, it has been shown that VMAT
needs more MU than IMRT. Earlier investigations using similar equip-
ment (TPS and linac manufacturer)18,43 conﬁrm this result for prostate
carcinoma treatment. Other studies found reverse results,39,44–46 but
referred to RapidArc compared to sliding window IMRT, which needs
more MU than our step-and-shoot technique. For the re-irradiation of
spinal column metastasis with the same equipment as the present
study,16 there was no difference in the number of MU between IMRT
and VMAT which can be taken as an example that different targets
must be investigated individually.
It has been mentioned in the introduction that FFF aimed to
shorter treatment times especially for radiosurgical applications. The
beneﬁt which is demonstrated in our investigation is rather small
compared to the enabled maximum dose rate. The ﬁrst reason is,
that more MU are required per fraction dose for FFF than for FB as
described above. For VMAT, additionally higher dose rate values
than possible with FB are not exploited between all control points
of the whole arc as there are limiting factors like leaf speed and gan-
try speed. Thus, the delivery time of VMAT-FFF is 8% shorter than
for FB and yields a further reduction of the probability for intrafrac-
tion movement of the target. VMAT in both modes is therefore well
in the time interval of 2–3 min where no additional position veriﬁca-
tion and correction is required.47
5 | CONCLUSIONS
Taking all results into account, for the given equipment and the
treatment of patients with prostate carcinoma, a VMAT technique
with FFF mode is recommended. It combines the best plan quality
with fastest delivery and lowest PD.
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